Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection

Journal of Neuroscience Methods

Volumn 159, Issue 2, 2007, Pages 291-299

  Stephenson, Diane ^a   Ramirez, Andres ^a   Long, Jill ^a   Barrezueta, Nestor ^a   Hajos Korcsok, Eva ^a   Matherne, Curt ^a   Gallagher, Dan ^a   Ryan, Anne ^a   Ochoa, Ricardo ^a   Menniti, Frank ^a   Yan, James ^a  

^a PFIZER INC   (United States)

Author keywords

Actin; Dopamine; Immunohistochemistry; Laser capture microdissection; MPTP; Parkinson's disease; Quantitative Western blot; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BETA ACTIN; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COMPARATIVE STUDY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; HISTOLOGY; IMMUNOCYTOCHEMISTRY; LASER; LASER PRESSURE CATAPULTING; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DOPAMINE; IMMUNOHISTOCHEMISTRY; LASERS; MALE; MICE; MICE, INBRED C57BL; MICRODISSECTION; MPTP POISONING; NERVE DEGENERATION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33845390303     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2006.07.027     Document Type: Article

References (33)

1. Aguirre J.A., Kehr J., Yoshitake T., Liu F.-L., Rivera A., Fernandez-Espinola S., et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033 (2005) 216-220
2. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. BioEssays 24 (2002) 308-316
3. Bezard E., Dovero S., Bioulac B., and Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 148 (1997) 288-292
4. Bohm C., Newrzella D., and Sorgenfrei O. Laser microdissection in CNS research. Drug Discovery Today 10 (2005) 1167-1174
5. Brooks D.J. Neuroimaging in Parkinson's disease. NeuroRx 1 (2004) 243-254
6. Chung C.Y., Seo H., Sonntag K.C., Brooks A., Lin L., and Isacson L. Cell type specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14 (2005) 1709-1725
7. Dawson T.M., Mandir A.S., and Lee M.K. Animal models of PD: pieces of the same puzzle?. Neuron 35 (2002) 219-222
8. Emborg M.E. Evaluation of animal models of Parkinson's disease. J Neurosci Meth 139 (2004) 121-143
9. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor D., Brown W.D., et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401 (1998) 253-265
10. Fearnley J.M., and Lees A.J. Ageing Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
11. Feng Z.-H., Wang T.G., Li D.D., Fung P., Wilson B.C., Liu B., et al. Cyclooxygenase-2 deficient mice are resistant to 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329 (2002) 354-358
12. Giovanni A., Sonsalla P.K., and Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Part 1: systemic administration. J Pharmacol Exp Ther 270 (1994) 1000-1007
13. Gupta M., Gupta B.K., Thomas R., Bruemmer V., Sladek R.J., and Felton D.L. Aged mice are more sensitive to MPTP treatment than young adults. Neurosci Lett 70 (1986) 326-331
14. Haycock J. Quantitation of tyrosine hydroxylase protein levels: spot immunolabeling with an affinity purified antibody. Anal Biochem 181 (1989) 259-286
15. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
16. Jakowec M.W., Nixon K., Hogg E., McNeill T., and Petzinger G.M. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res 76 (2004) 539-550
17. Kamme F., Salunga R., Yu J., Tran D.-T., Zhu J., Luo L., et al. Single cell microarray analysis in hippocampus CA1: demonstration and validation of cellular heterogeneity. J Neurosci 23 (2003) 3607-3615
18. Korzhevskii D.E., Grigor'ev I.P., and Otellin V.A. Immunocytochemical demonstration of catcholaminergic structures in paraffin sections of the rat brain using various methods of fixation. Morfologiia 127 (2005) 63-64
19. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H., and Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neruosci 17 (2003) 1-12
20. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5 (1999) 1403-1409
21. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., et al. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J Neurosci 24 (2004) 7445-7454
22. Paxinos G., and Franklin K. The mouse brain in stereotaxic coordinates (2001), Academic Press, New York
23. Pickel V.M. Immunocytochemical localization of neuronal antigens: tyrosine hydroxylase, substance P, [Met5]-enkephalin. Fed Proc 38 (1979) 2374-2380
24. Plantier M., Der Terrossan E., and Repressa A. Beta-actin immunoreactivity in rat microglial cells: developmental pattern and participation in microglial reaction after kainate injury. Neurosci Lett 247 (1988) 49-52
25. Przedborski S., and Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res 1 (2001) 407-418
26. Sanna P.P., King A.R., van der Stap L.D., and Repunte-Canonigo V. Gene profiling of laser-microdissected regions and sub-regions. Brain Res Protocols 15 (2005) 66-74
27. Sedelis M., Schwarting R.K.W., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125 (2001) 109-122
28. Seniuk N.A., Tatton W.G., and Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527 (1990) 7-20
29. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsoon G. Studies on the effect of MPTP on central catecholamine neurons in C57Bl/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
30. Stephenson D.T., Li Q., Simmons C., Connell M.A., Meglasson M.D., Merchant K., et al. Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiol Dis 20 (2005) 347-359
31. Vincent V.A., DeVoss J.J., Ryan H.S., and Murphy J.M. Analysis of neuronal gene expression with laser capture microdissection. J Neurosci Res 69 (2002) 578-586
32. Waldeier P., Spooren W.P.J.M., and Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Arch Pharmacol 362 (2000) 526-537
33. Xu Z., Cawthon D., McCastlain K.A., Slikker, and Ali S.F. Selective alterations of gene expression in mice induced by MPTP. Synapse 55 (2005) 45-51